SEC Form SC 13G filed by Akoya BioSciences Inc.

CUSIP No.	00974H104
1.	Names of Reporting Persons   aMoon Growth Fund II, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☑ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	Sole Voting Power   0
	6.	Shared Voting Power   2,500,000
	7.	Sole Dispositive Power   0
	8.	Shared Dispositive Power   2,500,000
9.	Aggregate Amount Beneficially Owned by Each Reporting Person   2,500,000
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ☐
11.	Percent of Class Represented by Amount in Row (9)   5.16%(1)
12.	Type of Reporting Person (See Instructions)   PN

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

(1)	Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.

1.

aMoon Growth Fund II, L.P. (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

2.

aMoon Growth Fund II G.P., L.P. (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

3.

aMoon Growth II General Partner Ltd., (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

4.

aMoon Edge Limited Partnership (“aMoon Edge”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

5.

aMoon Edge GP Ltd., (“aMoon Edge Ltd.”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

6.

Hilliyon Holdings Ltd., (“Hilliyon”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

7.

Berko Capital Ltd., an Israeli company (“Berko Capital”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

8.

Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

9.

Dr. Tomer Berkovitz (“Berkovitz”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.

Item 3

If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

(a)

Amount beneficially owned:  2,500,000 shares of Common Stock.

(b)

Percent of Class: 5.16%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned:  2,500,000 shares of Common Stock.

(b)

Percent of Class: 5.16%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned:  2,500,000 shares of Common Stock.

(b)

Percent of Class: 5.16%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned:  418,439 shares of Common Stock.

(b)

Percent of Class: 0.86%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned:  418,439 shares of Common Stock.

(b)

Percent of Class: 0.86%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned:  418,439 shares of Common Stock.

(b)

Percent of Class: 0.86%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(iv)

Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.

(a)

Amount beneficially owned:  418,439 shares of Common Stock.

(b)

Percent of Class: 0.86%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 418,439 shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(iv)

Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.

(a)

Amount beneficially owned: 2,918,439 shares of Common Stock.  (i) Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon; (ii) aMoon Edge Ltd. is the sole general partner of aMoon Edge pursuant to the terms of the limited partnership agreement of aMoon Edge.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd. and Schindel is the sole shareholder of Hilliyon. By virtue of such relationships, Schindel may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. aMoon Ltd., aMoon Edge, aMoon Edge Ltd., and Hilliyon, except to the extent of his pecuniary interest therein, if any.

(b)

Percent of Class: 6.03%

(c)

Number of shares as to which the  person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 2,918,439  shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

(a)

Amount beneficially owned: 418,439 shares of Common Stock.  Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd., and Berkovitz is the sole shareholder of Berko Capital. By virtue of such relationships, Berkovitz may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Berkovitz disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon Edge, aMoon Edge Ltd. and Berko Capital, except to the extent of his pecuniary interest therein, if any.

(b)

Percent of Class: 0.86%

(c)

Number of shares as to which the  person has:

(i)

Sole power to vote or direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 418,439  shares of Common Stock

(iii)

Sole power to dispose or to direct the disposition of: 0

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Item 8

Identification and Classification of Members of the Group

EXHIBIT A TO SCHEDULE 13G Joint Filing Agreement The undersigned hereby agree that the Schedule 13G (the “Schedule 13G”), filed by the undersigned with respect to shares of Common Stock, par value $0.00001 per share, of Akoya Biosciences, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13G.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.   IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement this 13th day of June 2023.